Share Share on Facebook Share on Twitter Pinterest Email Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com 0 Related Posts Cobalt Market 2024 Year-End Review January 11, 2025 Lead Price Forecast: Top Trends for Lead in 2025 January 11, 2025 Nickel Price Forecast: Top Trends for Nickel in 2025 January 11, 2025